文献速递心力衰竭与心肌病

达格列净在射血分数轻度降低或保留的心力衰竭中的利尿剂使用:DELIVER试验

Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial.
PubMed 文献 · Eur Heart J · 2023-01-01

DELIVER试验预设分析评估达格列净在射血分数轻度降低或保留心衰患者中按基线利尿剂分层的影响。6263例随机患者中,达格列净对主要复合终点的获益在利尿剂类别或袢利尿剂剂量间一致,严重不良事件相似,并减少袢利尿剂新启用。

要点

  • 达格列净在无利尿剂、非袢利尿剂及不同袢利尿剂剂量亚组中主要复合终点获益一致。
  • 达格列净使袢利尿剂新启用风险降低32%(HR 0.68;95%CI 0.55-0.84;P<0.001)。
  • 达格列净组袢利尿剂持续剂量增加较少、持续剂量减少较多,净差异-6.5%(95%CI -9.4至-3.6;P<0.001)。

核心结论

  • 在射血分数轻度降低或保留的心衰患者中,达格列净相对安慰剂的临床获益在广泛利尿剂类别和剂量间一致,安全性相似。
  • 达格列净显著减少随访期间袢利尿剂的新启用需求。

研究设计与样本

  • DELIVER试验的预设分析,纳入6263例随机患者,评估达格列净vs安慰剂在无利尿剂、非袢利尿剂及袢利尿剂(呋塞米等效剂量<40、40、>40 mg)亚组中的效果。

主要发现

  • 基线时683例(10.9%)未用利尿剂,769例(12.3%)用非袢利尿剂,4811例(76.8%)用袢利尿剂。
  • 达格列净对主要复合终点的疗效在利尿剂使用类别(Pinteraction=0.64)或袢利尿剂剂量(Pinteraction=0.57)间一致。
  • 达格列净与安慰剂严重不良事件相似,无论利尿剂使用或剂量。
  • 达格列净减少袢利尿剂新启用32%(HR 0.68;95%CI 0.55-0.84;P<0.001),未影响停药/中断(HR 0.98;95%CI 0.86-1.13;P=0.83)。
  • 达格列净组首次持续袢利尿剂剂量增加较少、持续剂量减少较多,净差异-6.5%(95%CI -9.4至-3.6;P<0.001)。

关键数值与推荐

  • 袢利尿剂新启用:HR 0.68(95%CI 0.55-0.84;P<0.001)。
  • 袢利尿剂停药/中断:HR 0.98(95%CI 0.86-1.13;P=0.83)。
  • 持续剂量增加/减少净差异:-6.5%(95%CI -9.4至-3.6;P<0.001)。
  • 袢利尿剂平均剂量纵向变化:安慰剂校正的治疗效应为-2.5 mg/年(95%CI -1.5至-3.7;P<0.001)。

临床怎么用

  • 对于射血分数轻度降低或保留的心衰患者,无论基线利尿剂类别或袢利尿剂剂量,均可考虑使用达格列净。
  • 达格列净可减少随访期间袢利尿剂的新启用和剂量升级,可能有助于简化利尿剂管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular death among patients with heart failure with mildly reduced or preserved ejection fraction. In this study, the safety and efficacy of dapagliflozin according to background diuretic therapy and the influence of dapagliflozin on longitudinal diuretic use were evaluated. METHODS AND RESULTS: In this pre-specified analysis of the Dapagliflozin Evaluation to Improve the LIVEs of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) trial, the effects of dapagliflozin vs. placebo were assessed in the following subgroups: no diuretic, non-loop diuretic, and loop diuretic furosemide equivalent doses of <40, 40, and >40 mg, respectively. Of the 6263 randomized patients, 683 (10.9%) were on no diuretic, 769 (12.3%) were on a non-loop diuretic, and 4811 (76.8%) were on a loop diuretic at baseline. Treatment benefits of dapagliflozin on the primary composite outcome were consistent by diuretic use categories (Pinteraction = 0.64) or loop diuretic dose (Pinteraction = 0.57). Serious adverse events were similar between dapagliflozin and placebo arms, irrespective of diuretic use or dosing. Dapagliflozin reduced new initiation of loop diuretics by 32% [hazard ratio (HR) 0.68; 95% confidence interval (CI): 0.55-0.84, P < 0.001] but did not influence discontinuations/disruptions (HR 0.98; 95% CI: 0.86-1.13, P = 0.83) in follow-up. First sustained loop diuretic dose increases were less frequent, and sustained dose decreases were more frequent in patients treated with dapagliflozin: net difference of -6.5% (95% CI: -9.4 to -3.6; P < 0.001). The mean dose of loop diuretic increased over time in the placebo arm, a longitudinal increase that was significantly attenuated with treatment with dapagliflozin (placebo-corrected treatment effect of -2.5 mg/year; 95% CI: -1.5, -3.7, P < 0.001). CONCLUSION: In patients with heart failure with mildly reduced or preserved ejection fraction, the clinical benefits of dapagliflozin relative to placebo were consistent across a wide range of diuretic categories and doses with a similar safety profile. Treatment with dapagliflozin significantly reduced new loop diuretic requirement over time.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Chatur S, Vaduganathan M, Claggett B, et al. Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial. Eur Heart J. 2023. PMID: 37220093. doi:10.1093/eurheartj/ehad283

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。